Agilis Ventures Healthcare & MedTech Growth

For private equity, growth equity & family offices

Healthcare companies worth owning are rarely in the market.

Agilis identifies medtech and healthcare businesses before they become institutional transactions — and helps investors create the conditions for those companies to become exceptional investments.

Request a Thesis Briefing See the deal lifecycle
Target company revenue
$5–100M
EBITDA, or a credible path to it
$1–15M
Proprietary investment theses in development
8–10
Ownership profile we focus on
Founder

The thesis

Three levels of visibility.
Only one of them is worth your origination budget.

Competition and entry valuation are set long before diligence begins — by where the company sits on this spectrum when you first meet it.

  1. Level 1

    Auction

    The company has hired an investment banker. Everyone sees the book at the same time.

    High competition · high valuation

  2. Level 2

    Brokered

    Known to a handful of intermediaries. Moderate competition, partial information.

    Moderate competition

  3. Level 3 — where Agilis works

    Proprietary

    The founder hasn’t decided to sell. The company isn’t in the market. Agilis identifies it, builds the relationship and develops the investment thesis.

    Low competition · highest value creation

The Agilis deal lifecycle

From market map to exit.

Ten stages, run in sequence. Agilis can participate across the whole lifecycle or at the stage where you need the capacity.

  1. Identify

    Build the company universe inside a defined thesis — typically 100–500 businesses.

  2. Screen

    Score each one against the Agilis Investment Opportunity Score.

  3. Develop

    Research ownership, financial profile, market position and management.

  4. Engage

    Build a direct relationship with the founder or CEO — ahead of any process.

  5. Qualify

    Determine whether a transaction opportunity actually exists.

  6. Introduce

    Match the company to the right investment partner and structure.

  7. Execute

    Support commercial diligence and transaction strategy.

  8. Transform

    Go-to-market, sales organization, pricing and commercial KPIs post-close.

  9. Consolidate

    Identify and develop tuck-in acquisitions inside the platform.

  10. Exit

    Position the business for maximum strategic value.

What you receive

Not a lead.
An investment brief.

Every qualified target arrives with the founder context, the investment thesis, a value-creation plan and an acquisition path — the work an operating partner would otherwise do after the deal closes.

Medical Device Company X

Illustrative · Agilis Investment Brief

Revenue
$22M
EBITDA
$4M
Growth
12%
Market
$1.2B
Recurring
72%
Ownership
Founder

Investment thesis

  1. Attractive, highly fragmented market
  2. Regulatory moat and clinical evidence base
  3. High customer retention on recurring product
  4. Underpenetrated sales channel
  5. Founder has not institutionalized sales
  6. International opportunity untouched
  7. Five to ten identified tuck-in candidates
Revenue
$22M $45M
EBITDA
$4M $10M
Multiple
8x 10x

Illustrative example only. Figures are hypothetical and do not represent an actual company or transaction.

Agilis Investment Opportunity Score™

Each company is scored across fourteen dimensions — market attractiveness, growth, recurring revenue, gross margin, regulatory and clinical moat, switching costs, customer concentration, management quality, founder willingness, acquisition fit, add-on potential, international opportunity and commercial upside.

85–100
Priority targetActively developed and introduced
70–84
Develop relationshipFounder engagement begins
55–69
MonitorTracked for a change in circumstance
Below 55
PassDocumented and removed from the funnel

The sweet spot

What an attractive Agilis target looks like.

We don’t cover all of healthcare. The concentration is medtech and healthcare businesses in the lower middle market, where commercial professionalization is the value-creation lever.

  1. Differentiated product or technology
  2. Meaningful clinical or economic value
  3. Recurring or repeat-use products
  4. Strong clinical and regulatory barriers
  5. Fragmented or evolving market
  6. Founder or family ownership
  7. Established customer adoption
  8. Underdeveloped commercial infrastructure
  9. Attractive healthcare economics
  10. Room to professionalize management
  11. Buy-and-build potential
  12. Repeatable path to growth

The company does not need to have everything figured out. That is usually where Agilis creates the most value.

Who we work with

Three kinds of capital.

Lower-Middle-Market Healthcare PE

$250M–$2B funds · $5–20M EBITDA targets

Funds with sector-specific theses, operating partners and pressure to find proprietary deals — but limited internal sourcing capacity. Agilis becomes the external medtech origination arm.

Growth Equity & Healthcare VC

$5–50M revenue · pre-institutional round

Companies with regulatory approval, clinical traction and commercial proof that need capital to scale. Agilis identifies them before their next financing.

Family Offices & Independent Sponsors

Capital without an internal healthcare team

Investment appetite and capital, but limited healthcare expertise and sourcing infrastructure. Agilis becomes the healthcare investment office they don’t have internally.

Engagement

Aligned across the funnel, not only at the close.

Agilis works on a retained basis for origination and thesis development, with transaction and portfolio economics layered on where the mandate calls for it.

Origination Mandate

Monthly retainer

Sector research, thesis development, target identification, founder mapping and pipeline management inside a defined investment theme.

Transaction Participation

Economics agreed per mandate

Scaled to how much of the transaction process Agilis carries — from introduction through commercial diligence and deal strategy.

Portfolio Value Creation

Monthly retainer, post-close

External commercial and M&A operating partner: GTM strategy, sales organization, pricing, add-on identification, KPI architecture and CEO advisory.

Strategic Projects

Fixed scope

Commercial diligence, market entry, category design, pricing strategy, investor readiness and 100-day planning.

Request a thesis briefing

Start with a thesis, not a target list.

Tell us the sector you’re trying to own. We’ll walk you through the market map, the fragmentation picture, the company universe and where the proprietary opportunities sit.

Principal
Jeff EardleyFounder & Managing Partner
Email
Location
Ada, Michigan
LinkedIn
linkedin.com/in/jeffeardley